Leon Chien‐Wei Lin

Leon Chien‐Wei Lin

Auto-generated profile, based on publicly available information

Leon Chien‐Wei Lin

John Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2013 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
NCNathan Croft
Nathan Croft
SSStewart A. Smith
Stewart A. Smith
YWYik Chun Wong
Yik Chun Wong
CTChor Teck Tan
Chor Teck Tan
NDNadine L. Dudek
Nadine L. Dudek
Anthony PurcellAnthony Purcell
Anthony Purcell
Current knowledge about the dynamics of antigen presentation to T cells during viral infection is very poor despite being of fundamental importance to our understanding of anti-viral immunity. Here we use an advanced mass spectrometry method to simultaneously quantify the presentation of eight vaccinia virus peptide-MHC complexes (epitopes) on infected cells and the amounts of their source antigens at multiple times after infection. The results show a startling 1000-fold range in abundance as well as strikingly different kinetics across the epitopes monitored. The tight correlation between onset of protein expression and epitope display for most antigens provides the strongest support to date that antigen presentation is largely linked to translation and not later degradation of antigens. Finally, we show a complete disconnect between the epitope abundance and immunodominance hierarchy of these eight epitopes. This study highlights the complexity of viral antigen presentation by the host and demonstrates the weakness of simple models that assume total protein levels are directly linked to epitope presentation and immunogenicity. A major mechanism for the detection of virus infection is the recognition by T cells of short peptide fragments (epitopes) derived from the degradation of intracellular proteins presented at the cell surface in a complex with class I MHC. Whilst the mechanics of antigen degradation and the loading of peptides onto MHC are now well understood, the kinetics of epitope presentation have only been studied for individual model antigens. We addressed this issue by studying vaccinia virus, best known as the smallpox vaccine, using advanced mass spectrometry. Precise and simultaneous quantification of multiple peptide-MHC complexes showed that the surface of infected cells provides a surprisingly dynamic landscape from the point of view of anti-viral T cells. Further, concurrent measurement of virus protein levels demonstrated that in most cases, peak presentation of epitopes occurs at the same time or precedes the time of maximum protein build up. Finally, we found a complete disconnect between the abundance of epitopes on infected cells and the size of the responding T cell populations. These data provide new insights into how virus infected cells are seen by T cells, which is crucial to our understanding of anti-viral immunity and development of vaccines.

12 April 2019 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
LLLeon Chien‐Wei Lin
Leon Chien‐Wei Lin
CHChen‐Yu Huang
Chen‐Yu Huang
BYBing‐Yu Yao
Bing‐Yu Yao
JLJung‐Chen Lin
Jung‐Chen Lin
AAAnurodh Agrawal
Anurodh Agrawal
Jack HuJack Hu
Jack Hu

6 March 2018 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
LLLeon Chien‐Wei Lin
Leon Chien‐Wei Lin
SCSaborni Chattopadhyay
Saborni Chattopadhyay
JLJung‐Chen Lin
Jung‐Chen Lin
Jack HuJack Hu
Jack Hu

1 November 2018 in Mucosal Immunology
Verified
Journal Article
Closed access
PDF file
MFManuela Flórido
Manuela Flórido
HMHeni Muflihah
Heni Muflihah
LLLeon C. W. Lin
Leon C. W. Lin
YXYingju Xia
Yingju Xia
FSFrederic Sierro
Frederic Sierro
WBWarwick Britton
Warwick Britton

7 March 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
AAAnneliese S. Ashhurst
Anneliese S. Ashhurst
MFManuela Flórido
Manuela Flórido
LLLeon C. W. Lin
Leon C. W. Lin
DQDiana Quan
Diana Quan
EAEllis Armitage
Ellis Armitage
WBWarwick Britton
Warwick Britton
T-lymphocytes are critical for protection against respiratory infections, such as Mycobacterium tuberculosis and influenza virus, with chemokine receptors playing an important role in directing these cells to the lungs. CXCR6 is expressed by activated T-lymphocytes and its ligand, CXCL16, is constitutively expressed by the bronchial epithelia, suggesting a role in T-lymphocyte recruitment and retention. However, it is unknown whether CXCR6 is required in responses to pulmonary infection, particularly on CD4+ T-lymphocytes. Analysis of CXCR6-reporter mice revealed that in naïve mice, lung leukocyte expression of CXCR6 was largely restricted to a small population of T-lymphocytes, but this population was highly upregulated after either infection. Nevertheless, pulmonary infection of CXCR6-deficient mice with M. tuberculosis or recombinant influenza A virus expressing P25 peptide (rIAV-P25), an I-Ab-restricted epitope from the immunodominant mycobacterial antigen, Ag85B, demonstrated that the receptor was redundant for recruitment of T-lymphocytes to the lungs. Interestingly, CXCR6-deficiency resulted in reduced bacterial burden in the lungs 6 weeks after M. tuberculosis infection, and reduced weight loss after rIAV-P25 infection compared to wild type controls. This was paradoxically associated with a decrease in Th1-cytokine responses in the lung parenchyma. Adoptive transfer of P25-specific CXCR6-deficient T-lymphocytes into WT mice revealed that this functional change in Th1-cytokine production was not due to a T-lymphocyte intrinsic mechanism. Moreover, there was no reduction in the number or function of CD4+ and CD8+ tissue resident memory cells in the lungs of CXCR6-deficient mice. Although CXCR6 was not required for T-lymphocyte recruitment or retention in the lungs, CXCR6 influenced the kinetics of the inflammatory response so that deficiency led to increased host control of M. tuberculosis and influenza virus.

19 March 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AAAnneliese S Ashhurst
Anneliese S Ashhurst
TPTHAIGARAJAN PARUMASIVAM
THAIGARAJAN PARUMASIVAM
JCJohn Gar Yan Chan
John Gar Yan Chan
LLLeon C W Lin
Leon C W Lin
MFManuela Flórido
Manuela Flórido
WBWarwick Britton
Warwick Britton
Tuberculosis places a staggering burden on human health globally. The new World Health Organisation End-TB Strategy has highlighted the urgent need for more effective TB vaccines to improve control of the disease. Protein-based subunit vaccines offer potential as safe and effective generators of protective immunity, and the use of particulate vaccine formulation and delivery by the pulmonary route may enhance local immunogenicity. In this study, novel particulate subunit vaccines were developed utilising biodegradable poly(lactic-co-glycolic acid) (PLGA) slow-release particles as carriers for the Mycobacterium tuberculosis lipoprotein MPT83, together with the adjuvants trehalose-dibehenate (TDB) or Monophosphoryl lipid A (MPL). Following delivery by the pulmonary or subcutaneous routes, the immunogenicity and protective efficacy of these vaccines were assessed in a murine model of M. tuberculosis infection. When delivered peripherally, these vaccines induced modest, antigen-specific Th1 and Th17 responses, but strong anti-MPT83 antibody responses. Mucosal delivery of the PLGA(MPT83) vaccine, with or without TDB, increased antigen-specific Th17 responses in the lungs, however, PLGA-encapsulated vaccines did not provide protection against M. tuberculosis challenge. By contrast, peripheral delivery of DDA liposomes containing MPT83 and TDB or MPL, stimulated both Th1 and Th17 responses and generated protection against M. tuberculosis challenge. Therefore, PLGA-formulated vaccines primarily stimulate strong humoral immunity, or Th17 responses if used mucosally, and may be a suitable carrier for vaccines against extracellular pathogens. This study emphasises the critical nature of the vaccine carrier, adjuvant and route of delivery for optimising vaccine efficacy against TB.